   |
ASH feedback/research update Read the latest Incyte press release or visit the Incyte website, where you can view the presentations on Incyte given at the most recent (December 2009) American Society of Hematology meeting. JAK2 inhibitor study will open in 8 UK centres including London, Sheffield, Oxford, Cambridge, Glasgow, Newcastle, Cardiff and Belfast (for patients with MF). You can read more information from previous American Society of Hematology (ASH) meetings on these links: There was also exciting provisional data suggesting that Revlimid (an anologie of thalidomide) might be useful in the treament of Myelofibrosis. The highlight of the ASH (American Society of Haematology) meeting in 2004 was the PT1 trial (see Scientific papers). Exciting data was also presented about the treatment of myelofibrosis. Highlights from ASH 2004  |
  |
 |
|||||||||
 |
 |
 |
 |
 |
 |
|||||
